



July 22, 2011 03:40 PM Eastern Daylight Time

Research and Markets: Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Assessment and Market Forecasts to 2017 - Changing Future Landscape of the PTSD Market

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8c34fa/posttraumatic_str) has announced the addition of GlobalData's new report "Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.

GlobalData, the industry analysis specialist, has released its new report, [Post-Traumatic Stress Disorder \(PTSD\) Therapeutics - Pipeline Assessment and Market Forecasts to 2017](#). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

“Post-Traumatic Stress Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”

PTSD Therapeutics Market is Forecast to Show Slow Growth until 2017

GlobalData estimates that the global Post - traumatic Stress Disorder (PTSD) therapeutics market was valued at \$2.2 billion in 2010, and it is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% over the next seven years, to reach \$2.9 billion by 2017. This slow growth is primarily attributed to low disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs. Need for First-in-Class Drugs

GlobalData's research indicates that the PTSD pipeline is weak with 16 molecules in various phases of clinical development. The first-in-class molecules seem to have distinct advantages over the current products in terms of better disease management. The unmet need of the PTSD market is low and treatment relies on older therapies and drugs. The market needs therapies offering better results in terms of safety and efficacy.

Changing Future Landscape of the PTSD Market

Columbia Northwest Pharmaceuticals, Synosia Therapeutics/Biotie Therapies and Sanofi-aventis are going to be the key players in the PTSD market. GlobalData has profiles of all these companies as they hold important pipeline drugs in Phase II of development for PTSD.

The existing market landscape remains competitive, because treatment of PTSD relies on established, older therapies such as Selective Serotonin Reuptake Inhibitors (SSRIs). The market scenario is expected to change after the launch of new therapies such as Alpha and Beta Adrenergic Receptor antagonists, N-methyl D-aspartate (NMDA) receptor modulators, Corticotropin Releasing Factor (CRF1) inhibitors, Progesterone receptor antagonist, V1 Receptor antagonists, and mGluR7 NAM inhibitor.

Companies Mentioned:

- Biotie Therapies
- Sanofi - Aventis
- Columbia Northwest Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/8c34fa/posttraumatic_str.

Contacts

Research and Markets
 Laura Wood, Senior Manager
press@researchandmarkets.com
 U.S. Fax: 646-607-1907
 Fax (outside U.S.): +353-1-481-1716

